AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03604770 — intervention group
Intervention type: OTHER
Intervention: Survey & Food Diary
Description: Patients will be provided with a 8 question patient survey to complete and return, as well as a food diary that they will complete over a 3 day period to assess their average caloric intake.
Study NCT06730568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Submarginal mechanical instrumentation
Description: Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. No adjunctive therapies were applied in this group.
Study NCT06730568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submarginal mechanical instrumentation and chlorhexidine irrigation
Description: The participants in the mechanical instrumentation with chlorhexidine (MC) group were treated with conventional submarginal instrumentation using titanium curettes. Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. Following mechanical instrumentation, the peri-implant pockets were irrigated with 0.2% chlorhexidine digluconate solution for 1 minute.
Study NCT06730568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submarginal mechanical instrumentation and ozone application
Description: The participants in the mechanical instrumentation with ozone (MO) group were treated with conventional submarginal instrumentation using titanium curettes. Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. Following mechanical instrumentation, gaseous ozone was applied to the peri-implant pockets using an ozone-generating device and a specialized glass fiber probe. The ozone gas was delivered to four sites (mesial, distal, buccal, and lingual) for 15 seconds per site, resulting in a total application time of 1 minute per implant. The device operated at a power of 3 watts and 80% oxygen concentration, as recommended by the manufacturer.
Study NCT06730568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submarginal mechanical instrumentation and air abrasion
Description: The participants in the mechanical instrumentation with glycine powder air abrasion (MA) group were treated with conventional submarginal instrumentation using titanium curettes. Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. Following mechanical instrumentation, the peri-implant pockets were treated with glycine powder-based air abrasion using an air-abrasion device (AIR-FLOW® handy 3.0 PERIO HANDPIECE, EMS, Nyon, Switzerland) and a flexible Perio-Flow® nozzle. The nozzle was inserted into the pockets and guided in a circular motion from coronal to apical, parallel to the implant surface, in a non-contact mode as recommended by the manufacturer. The air-abrasion treatment was applied to four sites (mesial, distal, buccal, and lingual) for 5 seconds per site, resulting in a total application time of 20 seconds per implant.
Study NCT06730568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air abrasion monotherapy
Description: The participants in the glycine powder air abrasion monotherapy (A) group were treated exclusively with glycine powder-based air abrasion. Local anesthesia was applied before the procedure. The peri-implant pockets were instrumented with an air-abrasion device using glycine powder and a flexible nozzle. The nozzle was inserted into the pockets and guided in a circular motion from coronal to apical, parallel to the implant surface, in a non-contact mode as recommended by the manufacturer. The air-abrasion treatment was applied to four sites (mesial, distal, buccal, and lingual) for 5 seconds per site, resulting in a total application time of 20 seconds per implant. .
Study NCT00380666 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET/CT scan
Study NCT01264848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: balloon angioplasty and/or stenting
Description: balloon angioplasty and/or stenting of internal jugular veins and/or azygous vein and/or brachiocephalic veins
Study NCT01264848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: balloon angioplasty and/or stenting
Description: balloon angioplasty and/or stenting of extracranial vein draining the central nervous system, on condition that such outflow pathology has been confirmed using catheter venography
Study NCT05284929 — intervention group
Intervention type: GENETIC
Intervention: A single blood sample for HLA typing
Description: Extracting of DNA from the blood sample using PCR-reaction
Study NCT02849067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Treatment
Description: Patients in this group will watch a comedy show that will will not exceed 30 minutes. This group will have until five patients.
Study NCT02849067 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group Control
Description: patients in this group will watch a documentary that will not exceed 30 minutes. This will have until five patients
Study NCT01667939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI) in supervised pregnancies
Description: Dietetic treatment was calculated according to height, weeks of gestation and weight, considering an energy intake of 30 kcal/kg of expected weight, distributing the resulting energy according to the percentage of macronutrients' adequation (55-65% carbohydrates, 10-20% fat and the remainder as proteins).16 On each nutritional visit, 24 hour dietary recall was done and analyzed using NutriKcal®VO software in order to evaluate the Healthy Eating Index (HEI), which is commonly employed to assess pregnant women's dietary adequacy (on a scale from 0-100), through the consumption of 12 components of food groups described previously. An improvement in diet was considered when the initial HEI score improved more than one point during the next nutritional assessment.
Study NCT04007224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal oxytocin
Description: daily administration of oxytocin, 10 UI intrnasal, 5 UI bid, and if needed curcumin orally 250 mg bid, and/or lecithin 500 mg bid, and/or pironoquinolinquinone, 20 mg qd
Study NCT04007224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous umbilical cord blood
Description: patients aged between 3 and 7 years will receive one-time intravenously the processed umbilical cord blood collected at the respective child's birth
Study NCT00223964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrlecit (sodium ferric gluconate complex in sucrose injection)
Study NCT02680613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational SMS
Description: Behaviour change messages delivered via SMS developed with the theoretical guidance of the Health Belief Model.
Study NCT02680613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Travel Voucher
Description: A code for return public transportation to closest cervical cancer screening clinic included in the research.
Study NCT00078520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Level 1
Description: IL-2-B-CLL 2 x 10\^7; CD40L-B-CLL 0
Study NCT00078520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Level 2
Description: IL-2-B-CLL 2 x 10\^7; CD40L-B-CLL 2 x 10\^6
Study NCT00078520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Level 2- Fixed Dose
Description: IL-2-B-CLL 2 x 10\^7; CD40L-B-CLL 2 x 10\^7
Study NCT04626505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziltivekimab
Description: Administered subcutaneously (s.c., under skin) once every 4 weeks for 12 weeks
Study NCT04626505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (ziltivekimab)
Description: Administered s.c. once every 4 weeks for 12 weeks
Study NCT02655874 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Administered at day 1
Study NCT02655874 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Administered at day 1
Study NCT02655874 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Administered at day 180
Study NCT02655874 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus-diphtheria-pertussis vaccine
Description: Administered at day 180
Study NCT02104687 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flow group
Description: After induction, each patient will obtain Transesophageal Dopplerometry probe (CardioQ) in order to monitor the parameters of CI, FTc, PV and SVR.
Study NCT02104687 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Press group
Description: After induction, the parameters of MAP and CVP will be monitored in each of the patients.
Study NCT01687699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Study NCT03646539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of smartphone application (app)
Description: Use of a CBT-based automated conversational agent available as a mobile device smartphone application for the management of mood.
Study NCT03646539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual will include (but may not be limited to) the participant's 6-week postpartum follow-up visit with their obstetrics care team. Participants will be sent surveys to evaluate their depressive and anxiety symptoms.
Study NCT03646539 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual will include (but may not be limited to) the participant's 6-week postpartum follow-up visit with their obstetrics care team. Participants will be sent surveys to evaluate their depressive and anxiety symptoms.
Study NCT01913184 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AKITA
Study NCT01913184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKITA
Study NCT03988660 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating fibrocytes
Description: Peripheral blood samples were taken from the patients presented with right iliac fossa pain. Samples were collected in sodium heparin (EDTA). Circulating fibrocyte levels were determined by dual staining peripheral blood samples for CD4 and Col-1 using Fluorescence-Activated Cell Sorting (FACS) and correlated with histopathological diagnosis.
Study NCT04573270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PrimePro
Description: Intravenous Injection
Study NCT04573270 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Injection
Study NCT06018012 — intervention group
Intervention type: DEVICE
Intervention: MRS and ABR
Description: Magnetic Resonance Spectroscopy and Auditory Brain- stem Response Audiometry
Study NCT03332537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized IBS Pain SM
Study NCT04675892 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A1 pulley division
Description: Local anesthesia with 5-10 ml of solution required (90 % lidocaine 1 % with 1 ug epinephrine, 10 % sodium bicarbonate 8.4 %).~Division of the A1 pulley.~Wound closure with absorbable sutures and application of a light dressing.
Study NCT04675892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A1 pulley division + Resection of one or both slips of the FDS tendon
Description: Local anesthesia with 5-10 ml of solution required (90 % lidocaine 1 % with 1 ug epinephrine, 10 % sodium bicarbonate 8.4 %).~Division of the A1 pulley.~Palmar Bruner incision over the PIP joint. Distal dissection and resection of one or both slips of the FDS tendon.~Wound closure with absorbable sutures and application of a light dressing.
Study NCT02668003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: The CBT intervention, delivered by telephone, will consist of an initial assessment, 6 weekly sessions, and then booster sessions at 3 and 6 months. The intervention will be delivered by trained and accredited therapists. Participants will be supported by a self-management CBT manual. There will be a patient-centred assessment by the therapist for problem identification, risk assessment and development of a shared formulation of the current health problem. The sessions will involve education about musculoskeletal pain, somatic symptoms and specific CBT techniques such as pacing of activity, behavioural activation, diary keeping, identifying and challenging negative and unhelpful thinking patterns and the development of a longer term management plan.
Study NCT02678819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital cognitive aid
Description: Digital cognitive aid during anesthesia and intensive care crises.
Study NCT03893786 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Rehabilitation
Description: Fifteen patients with Parkinson's Disease will perform ten 45-minute training sessions of the upper limb bilaterally with the Armeo®Spring, an electromedicad device aimed at improving force and coordination in neurologically affected patients.~The device was built to sustain the forearm during the upperlimb training and is equipped with a VR screen with which the patient may interact during the playful and motivating rehab.
Study NCT00093847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-adenosyl methione (SAMe)
Description: Oral SAMe tosylate, up to 1600 mg per day for 6 weeks
Study NCT00093847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be taken daily for 6 weeks
Study NCT02719938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialty Palliative Care
Description: Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
Study NCT01650545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal aerosol cyclosporine
Description: inhaled form of immune suppression
Study NCT01650545 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard immune suppression, oral
Description: conventional drug~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone and rapamycin
Study NCT01650545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard immune suppression, oral
Description: conventional drug~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone and rapamycin
Study NCT03838406 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: BRCA 1
Description: The investigators evaluated the incidence of BRCA loss in patients with advanced gastric cancer and observed the treatment outcome and prognosis.
Study NCT03838406 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BRCA 1
Description: The investigators evaluated the incidence of BRCA loss in patients with advanced gastric cancer and observed the treatment outcome and prognosis.
Study NCT03838406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days.
Study NCT03838406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days.
Study NCT00876226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Citalopram pharmacokinetics will be studies in subjects with short bowel syndrome.~Citalopram 20mg orally will be given to the subjects and on the seventh day blood will be drawn at hours 0,1,2,3,4,6,8,12,16 and 24 hours post-dose.
Study NCT04253405 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Catheter
Description: HFNC will be delivered through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.~Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize the patient´s comfort and SpO2
Study NCT04253405 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive positive pressure ventilation (NIPPV)
Description: NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 according to the protocol.
Study NCT03650725 — intervention group
Intervention type: OTHER
Intervention: Mandatory Split bowel preparation
Description: Intervention describes the standard of care patient split bowel preparation instructions as mandatory, instead of giving patient instructions with option of choice between split or day before bowel prep.
Study NCT03279796 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived MSCs
Description: The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 \^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
Study NCT03279796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound betamethasone
Description: 1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.
Study NCT03201874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain self-management
Description: The program is designed to enhance self-efficacy. The app will guide youth in setting structured and personalized goals aimed at improving their pain and functioning. The pain self-management skills will include personalized CBT-based coping skills including deep breathing, relaxation, and cognitive skills (e.g., staying positive). The app will provide in-the-moment access to pain coping strategies to promote positive changes in mood, behavior, and pain.
Study NCT03201874 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education about sickle cell disease to increase disease knowledge
Study NCT03201874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education about sickle cell disease to increase disease knowledge
Study NCT00777322 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excimer laser ablation, and collagen cross-linking
Description: Surgery is performed with topical anaesthesia. The central corneal epithelium is removed. Excimer laser ablation is applied (typically 15-30 seconds). Residual bed thickness is checked with an ultrasonic pachymeter. Topical application of riboflavin 0.1% in dextran is commenced at 5 minute intervals. When an adequate saturation of the anterior chamber with riboflavin has been achieved, cross-linking treatment will proceed. Output from the UV light generating equipment is measured with a UV light meter and set at 3mW/cm². Thirty minutes of treatment is given, interrupted at five minute intervals by the application of more topical riboflavin drops. Finally the eye has a bandage soft contact lens placed, with preservative free topical antibiotic, steroid, and cycloplegic drop application.
Study NCT01647919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cogniVida™ 100 mg/day
Description: 4 capsules 25 mg (total 100 mg) cogniVida™ once a day
Study NCT01647919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules of placebo identical to cogniVida™ once a day
Study NCT00480493 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STEP
Description: Experimental: Minutes of parent mentor-parent participant interactions Control: Minutes of parent contact-parent participant interactions
Study NCT00480493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP
Description: Experimental: Minutes of parent mentor-parent participant interactions Control: Minutes of parent contact-parent participant interactions
Study NCT01131884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamax
Description: 70mg of Bisphosphonate therapy (Fosamax) will be taken weekly for a year
Study NCT01131884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.